Dexapos eye drops 1 mg/ml dropper bottle 5 ml

Dexapos eye drops are indicated in the treatment of severe eye inflammation of non-infectious origin, such as severe allergic eye diseases, severe inflammation of the conjunctiva, cornea and anterior segment of the eye, as well as inflammation in the postoperative period.

Composition

Active ingredient: dexamethasone;

1 ml 1 mg dexamethasone sodium metasulfobenzoate;

Excipients: thiomersal, hypromellose, glucose monohydrate, water for injections.

Contraindication

Method of application

The drug is intended for ophthalmic use.

The drug is instilled into the conjunctival sac of the affected eye 1 drop 3-5 times a day. According to the doctor's prescription, in case of especially severe acute conditions at the beginning of treatment, the drug Dexapos can be instilled more often.

Usually the course of treatment should not exceed 2 weeks. If no improvement is observed after the first 2 days of treatment, the feasibility of further therapy should be reconsidered.

When instilling eye drops, avoid any contact of the dropper tip with the eye or skin.

Application features

Pregnant women

Not recommended for use during pregnancy.

Children

Do not use on children.

Drivers

With caution.

Overdose

Possible clinical signs and symptoms of overdose (punctate keratitis, erythema, increased lacrimation, eyelid edema and itching) may be similar to the adverse reactions observed in some patients. Prolonged intensive use may lead to systemic side effects.

In case of overdose with topical application, wash excess drug from the eye(s) with warm water. Treatment is symptomatic.

Side effects

The most common adverse reactions observed during clinical trials of Dexapos were ocular discomfort, keratitis, and eye irritation, occurring in 0.7 to 0.9% of patients.

Interaction

Concomitant use of topical steroids and topical nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of corneal wound healing complications.

CYP3A4 inhibitors (including ritonavir and cobicistat) may reduce dexamethasone clearance and increase the adrenal suppression/Cushing's syndrome effect. Such combinations should be avoided unless the benefit outweighs the risk of increased systemic side effects of the glucocorticosteroid, in which case careful monitoring of systemic effects of the glucocorticosteroid should be performed.

In case of concomitant therapy with other topical ophthalmic drugs, an interval of 10-15 minutes should be observed between their instillations. Eye ointments should be used last.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf life - 2 years.